|
Amylin Pharmaceuticals helps diabetics gain the upper hand in their battle with the disease. The company makes and markets two injectable diabetes drugs, Byetta and Symlin, that are approved as adjunct therapies to other diabetes treatments such as metformin and insulin. Development partner Eli Lilly markets Byetta worldwide and is responsible for the development of Byetta in international markets. Amylin's US-based sales force co-promotes Byetta with Eli Lilly and markets Symlin on its own. The company is working on other diabetes drugs, including a once-weekly version of Byetta, as well as treatments for obesity.
|
| | | Contact Information | |
Address: |
9360 Towne Centre Dr.
San Diego, CA 92121
| | Phone: | 858-552-2200 | | Fax: | 858-552-2212 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 840.10 M | | Revenue Growth (1 yr): | 7.60% | | Employees (2008): | 1,800 | | Employee Growth (1 yr): | (-5.30%) |
|
|
Key People
| | • |
President, CEO, and Director:
Daniel M. (Dan) Bradbury
| | • |
SVP Finance and CFO:
Mark G. Foletta
| | • |
VP Commercial Operations and Strategic Relationship Manageme:
Sarah L. Hanssen
|
|
|
